NEW YORK, October 24, 2016 /PRNewswire/ --
Pre-market, Stock-Callers.com has initiated coverage on the following equities: Valeant Pharmaceuticals International Inc. (NYSE: VRX), Skyline Medical Inc. (NASDAQ: SKLN), Baxter International Inc. (NYSE: BAX), and DENTSPLY International Inc. (NASDAQ: XRAY). These stocks belong to the Healthcare sector which struggled throughout the session on Friday, October 21, 2016, with the NYSE Health Care Index dropping almost 0.5%, and shares of health care companies in the S&P 500 falling nearly 0.8% as a group. Learn more about these stocks by accessing their free research reports at:
Shares in Laval, Canada headquartered Valeant Pharmaceuticals International Inc. ended Friday's session 0.45% lower at $21.96 with a total trading volume of 7.72 million shares. The stock is trading 17.65% below its 50-day moving average. Shares of the Company, which develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide, have a Relative Strength Index (RSI) of 30.21.
On October 14th, 2016, Valeant Pharmaceuticals announced that its Patient Access and Pricing Committee has made decisions regarding price changes of products in the company's neurology, GI and urology portfolios. These planned wholesale acquisition price changes, effective October 14th, 2016, range from 2.0% to 9.0%. The changes are aligned with the Committee's commitment that the average annual price increase for Valeant's prescription pharmaceutical products will be set at no greater than single digits and below the 5-year weighted average of the increases within the branded biopharmaceutical industry. The company's 2016 pricing actions across its U.S. branded Rx portfolio, represent an increase of less than 2.0% within the calendar 2016 year.
On October 14th, 2016, research firm Deutsche Bank reiterated its 'Hold' rating on the Company's stock with a decrease of the target price from $30 a share to $29 a share. Free research report on VRX is available at:
Eagan, Minnesota-based Skyline Medical Inc.'s stock saw a decline of 1.64%, closing the day at $0.12 with a total trading volume of 803,474 shares. Shares in the Company, which manufactures environmentally conscientious system for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care in the US, are trading 15.94% below their 50-day moving average. The stock has an RSI of 42.66.
As per notes filed with the SEC, on October 11th, 2016, Skyline Medical received a letter from the Listing Qualifications Department of The NASDAQ Stock Market LLC, indicating that the Staff had determined to delist the Company's securities from The Nasdaq Capital Market due to the Company's continued non-compliance with the minimum bid price requirement as of October 10th, 2016, unless the Company timely requests a hearing before the Nasdaq Hearings Pane. The Company plans to timely request a hearing before the Panel, which request will stay any delisting or suspension action by the Staff pending the issuance of the Panel's decision and the expiration of any extension granted by the Panel. The complimentary research report on SKLN can be downloaded at:
Last Friday, shares in Deerfield, Illinois headquartered Baxter International Inc. declined 0.02%, closing the session at $48.18. The stock recorded a trading volume of 3.66 million shares. The Company's shares have advanced 4.80% over the previous three months and 27.39% on an YTD basis. The stock is trading 1.87% above its 50-day moving average and 11.13% above its 200-day moving average. Furthermore, shares of Baxter International, which provides a portfolio of renal and hospital products, have an RSI of 55.90.
On October 13th, 2016, research firm Wells Fargo initiated an 'Outperform' rating on the Company's stock.
On October 19th, 2016, Baxter announced its recently launched SHARESOURCE remote patient management system has helped healthcare providers manage more than 150,000 peritoneal dialysis (PD) treatments performed in patients' homes. The treatment milestone represents the large-scale application of the first and only two-way, telehealth platform to support home dialysis therapy. Visit us today and access our complete research report on BAX at:
York, Pennsylvania headquartered DENTSPLY International Inc.'s stock finished the session 1.27% lower at $58.30 with a total trading volume of 989,496 shares. Shares of the Company, which designs, develops, manufactures, and markets various consumable dental products for the professional dental market in the US and internationally, are trading below their 50-day moving average by 2.56%. The stock has an RSI of 44.19.
On October 21st, 2016, DENTSPLY announced that the Company will report Q3 2016 financial results on November 4th, 2016, before the opening of the U.S. financial markets. DENTSPLY's management team will host an investor conference call and live webcast at 8:30 am EDT that morning. Get free access to your research report on XRAY at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA